Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

被引：0
|
作者：
Dalal, Rahul S. [1 ]
Clarke, Lindsay M. [1 ]
Carlin, Alex [1 ]
Cabral, Heidy [1 ]
Allegretti, Jessica R. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
来源：
INFLAMMATORY BOWEL DISEASES | 2024年
关键词：
ulcerative colitis; inflammatory bowel disease; biologics; bio-na & iuml; ve; INFLAMMATORY-BOWEL-DISEASE;
D O I：
10.1093/ibd/izae215
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-na & iuml;ve patients with ulcerative proctitis.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
    Long, Millie D.
    Smith, Timothy W.
    Dibonaventura, Marco
    Gruben, David
    Bargo, Danielle
    Salese, Leonardo
    Quirk, Daniel
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (06) : 941 - 948
  • [42] Real-world experience with a first-line niraparib maintenance monotherapy for advanced ovarian carcinoma
    Gregoric, Brigita
    Skof, Erik
    Skrbinc, Breda
    Geltar, Ana
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A220 - A220
  • [43] Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Response to Letter]
    de Castria, Tiago Biachi
    Kim, Richard D.
    PRAGMATIC AND OBSERVATIONAL RESEARCH, 2024, 15 : 91 - 92
  • [44] Real-world effectiveness of WHO recommended first-line antiretroviral therapies: a cohort study from a middle-income country
    Meireles, Glaucia
    Nobre, Aline A.
    Cardoso, Sandra W.
    Velasque, Luciane
    Veloso, Valdilea G.
    Grinsztejn, Beatriz
    Luz, Paula M.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2023, 35 (12): : 1891 - 1903
  • [45] Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
    Geynisman, Daniel M.
    Kish, Jonathan K.
    Falkenstein, Angelica
    Huo, Stephen
    Del Tejo, Viviana
    Rosenblatt, Lisa
    Guttenplan, Sarah
    Balanean, Alexandrina
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm
    Nieva, J.
    Chapaneri, J.
    Lau, Y. K.
    Cooper, M.
    Karia, P. S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S191 - S191
  • [47] Real-world time on treatment (rwToT) analysis for first-line pembrolizumab combination therapy in advanced nonsquamous NSCLC
    Liu, S. V.
    Hu, X.
    Li, Y.
    Burke, T.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S756 - S757
  • [48] Treatment Patterns: Targeted Therapies Indicated for First-Line Management of Metastatic Renal Cell Carcinoma in a Real-World Setting
    Hess, Gregory
    Borker, Rohit
    Fonseca, Eileen
    CLINICAL GENITOURINARY CANCER, 2013, 11 (02) : 161 - 167
  • [49] The Safety and Efficacy of Cadonilimab in the First-Line Treatment of Recurrent or Metastatic Cervical Cancer: A Retrospective, Real-World Study
    Jin, G.
    Wang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E693 - E693
  • [50] Comparative Effectiveness of Initial Therapy for Ulcerative Proctitis in Real-World Clinical Practice: A Retrospective Study
    Richter, James M.
    Oster, Gerry
    GASTROENTEROLOGY, 2013, 144 (05) : S211 - S211
12345